(Q34248529)

31 July 2017

1 reference

title

The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases (English)

1 reference

31 July 2017

Denny WA

1

1 reference

31 July 2017

publication date

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

issue

1-2

1 reference

31 July 2017

page(s)

51-56

1 reference

Discovering novel chemotherapeutic drugs for the third millennium

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

The epidermal growth factor receptor and its inhibition in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Role of HER2 gene overexpression in breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal gro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 7. 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2801%2901026-6

10.1016/S0014-827X(01)01026-6

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference